9.5 Drug Product Selection, Generic Substitution & DAW Codes
Key Takeaways
- Under the Hatch-Waxman Act of 1984 (FD&C Act § 505(j)), FDA approves therapeutically equivalent generics through Abbreviated New Drug Applications (ANDAs), enabling pharmacists to substitute AB-rated products for the prescribed brand.
- FDA's Orange Book assigns A-codes (AA, AB, AN, AO, AP, AT) to therapeutically equivalent products that may be substituted and B-codes (BC, BD, BX, and others) to products that are not therapeutically equivalent and must not be substituted without prescriber authorization.
- DAW Code 1 means 'Substitution Not Allowed by Prescriber' and requires dispensing the brand as written; DAW Code 0 means no product-selection instruction was given and the pharmacist follows state substitution law.
- Generic substitution is governed by state law—most states permit substitution of an AB-rated generic unless the prescriber writes 'dispense as written' or the patient requests the brand; a few states mandate generic substitution when a therapeutically equivalent product exists.
- Therapeutic substitution (switching to a different active ingredient within a drug class) is not routine generic substitution and requires prescriber authorization or a collaborative practice agreement.
9.5 Drug Product Selection, Generic Substitution & DAW Codes
MPJE Core Concept: "Product selection" is the pharmacist's decision to dispense a generic (therapeutically equivalent) drug in place of the brand-name product the prescriber wrote. The federal framework (Hatch-Waxman Act, FD&C Act § 505, FDA Orange Book) defines which products are substitutable; state law defines when the pharmacist may or must substitute. The MPJE tests both layers and the DAW claim codes that document the choice.
1. The Federal Framework: Hatch-Waxman & ANDA Approvals
The Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) created the modern generic-drug pathway. A manufacturer may obtain FDA approval of a generic copy of a brand Reference Listed Drug (RLD) through an Abbreviated New Drug Application (ANDA) under FD&C Act § 505(j). To approve an ANDA, FDA must find the generic is pharmaceutically equivalent (same active ingredient, dosage form, strength, route of administration) and bioequivalent to the RLD. A drug that is both pharmaceutically equivalent and bioequivalent is therapeutically equivalent—FDA's determination that it can be expected to have the same clinical effect and safety profile.
Only therapeutically equivalent products may be routinely substituted for one another without prescriber authorization.
2. The FDA Orange Book: Therapeutic Equivalence Codes
FDA publishes therapeutic-equivalence evaluations in "Approved Drug Products with Therapeutic Equivalence Evaluations" (the Orange Book). Each multisource product receives a two- or three-letter code; the first letter is decisive.
| First Letter | Meaning | Substitution Permitted? |
|---|---|---|
| A | FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products | Yes (if state law allows) |
| B | FDA does NOT consider the product therapeutically equivalent | No |
Common A-codes (substitutable): AA, AB, AN, AO, AP, AT. AB is the most common code for solid oral generics and means any bioequivalence concern has been resolved with evidence.
Common B-codes (do not substitute): BC, BD, BE, BN, BP, BR, BS, BT, BX. A B-rated product has a known or potential bioequivalence problem; the pharmacist must dispense the product as prescribed unless the prescriber explicitly authorizes the switch.
Exam trap: Two products can be pharmaceutically equivalent (same active ingredient, strength, dosage form) yet not therapeutically equivalent if one is B-rated—for example, a different dosage form or a formulation with unresolved bioequivalence. Substituting across an A↔B boundary is illegal substitution.
3. State Law: When May or Must the Pharmacist Substitute?
The federal Orange Book answers whether these products can be interchanged safely; state law answers whether the pharmacist may or must do so. Most state practice acts provide:
- Permissive substitution: The pharmacist may substitute an AB-rated generic unless the prescriber writes "dispense as written" / "DAW" / "brand medically necessary," or the patient requests the brand and pays any price difference.
- Mandatory substitution: Some states require dispensing the lowest-cost therapeutically equivalent generic unless a DAW exception is documented (common under Medicaid formularies).
- Restricted substitution for narrow-therapeutic-index (NTI) drugs: For drugs such as warfarin, levothyroxine, phenytoin, carbamazepine, theophylline, and valproate, some states restrict substitution or require explicit consent and monitoring even though the Orange Book may code the products AB. State law is the limiting rule.
- Documentation: Most states require the pharmacist to record the substitution, the NDC of the product actually dispensed, and—where applicable—pass any savings to the patient or third-party payer.
Therapeutic substitution (switching between different active ingredients within a drug class, e.g., lisinopril → losartan) is not routine generic substitution. A pharmacist may not unilaterally therapeutic-substitute; it requires a collaborative practice agreement or prescriber authorization.
4. DAW (Dispense As Written) Product-Selection Codes
Pharmacy claims transmit a DAW/product-selection code (the CMS standard, required for Medicare Part D and adopted by most payers) that documents the substitution decision:
| DAW Code | Meaning |
|---|---|
| 0 | No product selection indicated—pharmacist follows state substitution law |
| 1 | Substitution not allowed by prescriber (brand dispensed as written) |
| 2 | Substitution allowed—patient requested the product dispensed |
| 3 | Substitution allowed—pharmacist selected the product dispensed |
| 4 | Substitution allowed—generic drug not available |
| 5 | Substitution allowed—brand over-prescribed |
| 6 | Substitution allowed—override |
| 7 | Substitution not allowed—brand drug dispensed as generic |
| 8 | Substitution allowed—generic not available in marketplace |
| 9 | Other |
DAW 1 is the prescriber's lock: when "DAW" is written or checked, the pharmacist must dispense the brand or contact the prescriber to change the order. DAW 0 is the default when the prescriber gives no product-selection instruction; the pharmacist then applies state substitution rules. DAW 3 documents a pharmacist-initiated generic substitution.
Billing rule: Submitting a brand product on a generic-coded claim (or vice versa) without the correct DAW code is a common audit finding and may be treated as misrepresentation by Medicaid or a PBM.
5. MPJE Reasoning Pattern
- Determine whether the prescribed and dispensed products are therapeutically equivalent (Orange Book A vs. B).
- Apply state law on permissive/mandatory substitution and any NTI or DAW restriction.
- Confirm the prescriber did not write DAW / "brand necessary"; if so, dispense as written or obtain a new order.
- Record the substitution, the NDC dispensed, and the correct DAW code on the claim.
- Pass any allowable savings to the patient or payer where state law requires.
Bottom line: Federal law defines what is substitutable (Hatch-Waxman + Orange Book A-code); state law defines when you may or must substitute; the DAW code documents the decision on the claim.
Under the Hatch-Waxman Act, FDA approves a generic copy of a brand Reference Listed Drug through which regulatory pathway?
In the FDA Orange Book, a multisource product coded 'BC' is best described as:
A prescriber writes for a brand drug and checks 'Dispense As Written.' Which DAW product-selection code must the pharmacy transmit on the claim?
Which statement correctly distinguishes generic substitution from therapeutic substitution on the MPJE?